Preprocedural statin therapy reduces the risk and extent of cardiac biomarker release following percutaneous coronary intervention
Language English Country Japan Media print
Document type Journal Article
- MeSH
- Angina Pectoris therapy MeSH
- Angioplasty, Balloon, Coronary * MeSH
- Biomarkers metabolism MeSH
- Adult MeSH
- Myocardial Infarction prevention & control MeSH
- Coronary Angiography MeSH
- Middle Aged MeSH
- Humans MeSH
- Myocardium pathology MeSH
- Pilot Projects MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Simvastatin therapeutic use MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use MeSH
- Troponin blood MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Biomarkers MeSH
- Simvastatin MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors MeSH
- Troponin MeSH
This study evaluates the association between statin therapy in patients treated by percutaneous coronary intervention (PCI) for stable angina pectoris and postinterventional myocardial injury with subsequent long-term clinical outcome. Prospectively collected data on 400 consecutive patients with stable angina pectoris or evidence of inducible myocardial ischemia were analyzed. The incidence of myocardial infarction based on postinterventional release of troponin I>1.5 ng/ml was 12% in the statin pretreated patients and 20% in those not pretreated with statin therapy (P=0.04, odds ratio 1.84, 95% confidence interval 1.06-3.21). Of the patients experiencing a post-PCI troponin elevation>1.5 ng/ml, those pretreated with a statin pre-PCI had a lesser troponin elevation compared with those not receiving a statin pre-PCI (median: 2.9 ng/ml [1.9-11.5] vs 5.0 ng/ml [3.1-8.8]; P<0.001). In the multivariate model, preprocedural statin therapy was identified as the only independent negative predictor of procedure-related myocardial necrosis based on postprocedural troponin elevation. In the 21-month follow-up period, statin pretreated patients were observed to have fewer deaths, revascularizations, or myocardial infarction; however, this difference was not statistically significant. These results suggest that pretreatment with statins in patients undergoing PCI for stable angina pectoris reduces the risk and extent of procedure-related myocardial injury measured by troponin release.
See more in PubMed
N Engl J Med. 1995 Nov 16;333(20):1301-7 PubMed
Heart Vessels. 2003 Sep;18(4):171-6 PubMed
J Invasive Cardiol. 2002 Dec;14(12):735-40 PubMed
N Engl J Med. 1996 Oct 3;335(14):1001-9 PubMed
JAMA. 2001 Jul 4;286(1):64-70 PubMed
Int J Cardiol. 2004 Sep;96(3):461-6 PubMed
Lancet. 2001 Apr 7;357(9262):1063-8 PubMed
J Am Coll Cardiol. 1998 Feb;31(2):241-51 PubMed
Am J Physiol Heart Circ Physiol. 2003 Jul;285(1):H59-64 PubMed
J Am Coll Cardiol. 2000 Apr;35(5):1134-41 PubMed
Heart Vessels. 2004 Sep;19(5):213-20 PubMed
Am J Cardiol. 2001 Mar 15;87(6):771-4, A7 PubMed
Circulation. 1998 Mar 31;97(12):1129-35 PubMed
Lancet. 2002 Jul 6;360(9326):7-22 PubMed
Heart. 2002 Jun;87(6):549-53 PubMed
Circulation. 2002 Feb 12;105(6):739-45 PubMed
FASEB J. 2004 May;18(7):805-15 PubMed
Circulation. 2002 Feb 12;105(6):691-6 PubMed
Atherosclerosis. 2002 Mar;161(1):17-26 PubMed
Circulation. 2002 Oct 22;106(17):2180-3 PubMed
Coron Artery Dis. 2000 Sep;11(6):503-7 PubMed
Lancet. 1994 Nov 19;344(8934):1383-9 PubMed
Circulation. 2004 Aug 10;110(6):674-8 PubMed
JAMA. 2001 Jan 24-31;285(4):430-6 PubMed
Biochem Pharmacol. 2002 Aug 1;64(3):497-505 PubMed
JAMA. 2001 Apr 4;285(13):1711-8 PubMed
